PURPOSE: Chromosomal abnormalities, especially t(4;14) and del(17p), are major prognostic factors in patients with multiple myeloma (MM). However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy. PATIENTS AND METHODS: To answer this important question, we retrospectively analyzed a series of 1,890 patients (median age, 72 years; range, 66 to 94 years), including 1,095 with updated data on treatment modalities and survival. RESULTS: This large study first showed that the incidence of t(4;14) was not uniform over age, with a marked decrease in the oldest patients. Second, it showed that both t(4;14) and del(17p) retained their prognostic value in elderly patients treated with melphalan and prednisone-based chemotherapy. CONCLUSION: t(4;14) and del(17p) are major prognostic factors in elderly patients with MM, both for progression-free and overall survival, indicating that these two abnormalities should be investigated at diagnosis of MM, regardless of age.
PURPOSE:Chromosomal abnormalities, especially t(4;14) and del(17p), are major prognostic factors in patients with multiple myeloma (MM). However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy. PATIENTS AND METHODS: To answer this important question, we retrospectively analyzed a series of 1,890 patients (median age, 72 years; range, 66 to 94 years), including 1,095 with updated data on treatment modalities and survival. RESULTS: This large study first showed that the incidence of t(4;14) was not uniform over age, with a marked decrease in the oldest patients. Second, it showed that both t(4;14) and del(17p) retained their prognostic value in elderly patients treated with melphalan and prednisone-based chemotherapy. CONCLUSION: t(4;14) and del(17p) are major prognostic factors in elderly patients with MM, both for progression-free and overall survival, indicating that these two abnormalities should be investigated at diagnosis of MM, regardless of age.
Authors: Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Mark R Litzow; Kimberly J Henderson; Scott A Van Wier; Greg J Ahmann; Rafael Fonseca Journal: Blood Date: 2005-06-23 Impact factor: 22.113
Authors: M J Calasanz; J C Cigudosa; M D Odero; C Ferreira; M T Ardanaz; A Fraile; J L Carrasco; F Solé; B Cuesta; A Gullón Journal: Genes Chromosomes Cancer Date: 1997-02 Impact factor: 5.006
Authors: Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp Journal: Blood Date: 2003-02-06 Impact factor: 22.113
Authors: J L Laï; M Zandecki; J Y Mary; F Bernardi; V Izydorczyk; M Flactif; P Morel; J P Jouet; F Bauters; T Facon Journal: Blood Date: 1995-05-01 Impact factor: 22.113
Authors: Hervé Avet-Loiseau; Rafael Fonseca; David Siegel; Meletios A Dimopoulos; Ivan Špička; Tamás Masszi; Roman Hájek; Laura Rosiñol; Vesselina Goranova-Marinova; Georgi Mihaylov; Vladimír Maisnar; Maria-Victoria Mateos; Michael Wang; Ruben Niesvizky; Albert Oriol; Andrzej Jakubowiak; Jiri Minarik; Antonio Palumbo; William Bensinger; Vishal Kukreti; Dina Ben-Yehuda; A Keith Stewart; Mihaela Obreja; Philippe Moreau Journal: Blood Date: 2016-07-20 Impact factor: 22.113
Authors: Meletios A Dimopoulos; Katja C Weisel; Kevin W Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Philippe Moreau; Anne Banos; Albert Oriol; Laurent Garderet; Michele Cavo; Valentina Ivanova; Adrian Alegre; Joaquin Martinez-Lopez; Christine Chen; Andrew Spencer; Stefan Knop; Nizar J Bahlis; Christoph Renner; Xin Yu; Kevin Hong; Lars Sternas; Christian Jacques; Mohamed H Zaki; Jesus F San Miguel Journal: Haematologica Date: 2015-08-06 Impact factor: 9.941